Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for ...

Ways biopharma organizations and media brands can leverage coverage opportunities to help achieve respective audience goals ...

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

Does FDA publish CRL? In Septemeber, 2025, FDA announced that it will publish CRL’s promptly after they are received by their ...

Novartis partners with Monte Rosa Therapeutics in a $5.7 billion deal to develop innovative treatments for immune-mediated ...

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector ...

Persistence: After one year, 50%–60% of SPP patients remained on therapy compared to 30%–40% in the retail channel—a ...

The Aligos Therapeutics chairman, president, and CEO discusses his journey to building his own company and bringing an experienced team along with him.

The new administration has a different perspective of vaccines than the previous administration, causing confusion with the ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy ...

Drugmaker aims to simplify operations, speed up decision-making, and reinvest savings into diabetes and obesity growth ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for ...